1. At a Glance – The Multinational Maharaja of Margins
At ₹26,350 per share and a market cap of ₹55,994 Cr, Abbott India is that premium pharma stock which behaves like an imported luxury car — smooth engine, great mileage, but expensive servicing. The company delivered ₹1,724 Cr revenue and ₹376 Cr PAT in Q3 FY26 with a solid 27% operating margin. ROCE stands at a royal 46.2% and ROE at 35.7% — numbers that make most pharma CFOs cry softly into their spreadsheets.
And yet? The stock is down ~10.8% in 3 months and ~18.8% in 6 months. P/E is 36.7 — above the industry median of 28.3. Book value is ₹1,888 and price-to-book is a spicy 14x.
So the question is simple:
Is Abbott India a consistent compounder temporarily misunderstood… or a premium stock finally feeling gravity?
Let’s dissect this global desi hybrid.
2. Introduction – 80-Year-Old Pharma Veteran, Still Doing Pushups
Founded in 1944, Abbott India is the Indian arm of global giant Abbott Laboratories, which operates in 160 countries across diagnostics, devices, nutrition and pharma.
In India, however, Abbott India focuses mainly on branded generics. No flashy biotech moonshots. No vaccine nationalism drama. Just old-school, doctor-driven prescriptions and steady margin harvesting.
It has:
- 125+ products
- 7 brands in India’s Top 100
- 12 brands ranked #1 in their respective markets
- 3,250+ sales colleagues
- Exports contributing just 2% of revenue
This is largely an India-focused prescription pharma machine.
But here’s the fun part.
In November 2024, it launched PneumoShield 14 (PCV-14 vaccine).
In September 2024, it signed a patent license agreement with Takeda Pharmaceutical Company for Vonoprazan.
So they are not just milking legacy brands. They are quietly upgrading the portfolio.
Now the real question:
Is this growth strong enough to justify 36x earnings?
3. Business Model – WTF Do They Even
